Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -92,036 | -42,673 | -285,422 | -217,408 | -156,693 |
| Depreciation Amortization | -1,200 | -672 | -10,519 | -8,991 | -6,643 |
| Accounts receivable | -1,984 | 9,255 | -36,830 | -52,800 | -43,393 |
| Accounts payable and accrued liabilities | -11,706 | -5,737 | 4,954 | 2,200 | 5,727 |
| Other Working Capital | -14,263 | -19,054 | -79,318 | -67,560 | -44,181 |
| Other Operating Activity | 40,572 | 8,536 | 84,155 | 91,067 | 62,226 |
| Operating Cash Flow | $-80,617 | $-50,345 | $-322,980 | $-253,492 | $-182,957 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 21,516 | 38,390 | 290,223 | 208,589 | 136,029 |
| PPE Investments | -40 | N/A | -187 | -131 | N/A |
| Investing Cash Flow | $21,476 | $38,390 | $290,036 | $208,458 | $136,029 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 250,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 16,840 | 7,918 | 13,676 | 7,759 | 1,481 |
| Other Financing Activity | -6,152 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $260,688 | $7,918 | $13,676 | $7,759 | $1,481 |
| Beginning Cash Position | 135,032 | 135,032 | 154,300 | 154,300 | 154,300 |
| End Cash Position | 336,579 | 130,995 | 135,032 | 117,025 | 108,853 |
| Net Cash Flow | $201,547 | $-4,037 | $-19,268 | $-37,275 | $-45,447 |
| Free Cash Flow | |||||
| Operating Cash Flow | -80,617 | -50,345 | -322,980 | -253,492 | -182,957 |
| Capital Expenditure | -40 | N/A | -187 | -131 | N/A |
| Free Cash Flow | -80,657 | -50,345 | -323,167 | -253,623 | -182,957 |